✦ LIBER ✦

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study

✍ Scribed by A. Schulz; D. Garfield; W. Berry; D. Gordon; C. Lowery; M. Smith

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitomycin-C and capecitabine as third-li

✍ Do Hyoung Lim; Young Suk Park; Byeong-Bae Park; Sang Hoon Ji; Jeeyun Lee; Keon W 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 200 KB

A Multicenter Phase II Study of Docetaxe

✍ Takashi Ishikawa; Satoru Shimizu; Masaaki Inaba; Taro Asaga; Kiyohumi Katayama; 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 554 KB

Phase II Study of Irinotecan and Cetuxim

✍ Benedito A. Carneiro; Ramesh K. Ramanathan; Marwan G. Fakih; Smitha S. Krishnamu 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 359 KB

Phase II study of weekly irinotecan (CPT

✍ J. Cassinello; P. López-Alvarez; A. Martínez-Guisado; M. Valladares; G. Huidobro 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 106 KB

Sorafenib as a third line therapy in pat

✍ Lubomir Bodnar; Maria Górnas; Cezary Szczylik 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 148 KB

A phase II trial to evaluate gefitinib a

✍ A. Goncalves; M. Fabbro; C. Lhommé; L. Gladieff; J.-M. Extra; A. Floquet; L. Cha 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 192 KB